Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Ovarian Neoplasms 4Lung Neoplasms 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Advanced Malignant Solid Neoplasm 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × adavosertib × Clear all
NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
124 enrolled 17 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡